Evidence map›Paper›PMID 19890401›Full record

ArticlePloS one2009

Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection.

Vladimir Novitsky, Rui Wang, Lauren Margolin, Jeannie Baca, Lemme Kebaabetswe, Raabya Rossenkhan, Caitlin Bonney, Michaela Herzig, David Nkwe, Sikhulile Moyo and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  5. Phylogenetic approach to recover integration dates of latent HIV sequences within-host.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  6. Observational
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Intra-host evolutionary rates in HIV-1C env and gag during primary infection.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2013
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Vladimir NovitskyHarvard School of Public Health AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Rui Wang
Lauren Margolin
Jeannie Baca
Lemme Kebaabetswe
Raabya Rossenkhan
Caitlin Bonney
Michaela Herzig
David Nkwe
Sikhulile Moyo
Rosemary Musonda
Elias Woldegabriel
Erik van Widenfelt
Joseph Makhema
Stephen Lagakos
M Essex
Botswana Harvard AIDS Institute Partnership · BWHarvard University · US

Funding

INTERNATIONAL TRAINING IN AIDS-RELATED EPIDEMIOLOGYD43TW000004 · FIC · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 1988 to 2012
$13.4M
STATISTICAL METHODS IN AIDS RESEARCHR37AI024643 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 2001 to 2010
$2.8M
Markers of Viral Set Point in Primary HIV-1C InfectionR01AI057027 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI NOVITSKY, VLADIMIR A · 2005 to 2009
$2.2M
FIC NIH HHS D43 TW000004NIAID NIH HHS R01 AI057027NIAID NIH HHS R37 AI024643NIAID NIH HHS R37 AI24643
6 · The paper itself

Abstract

backgroundAiming to answer the broad question "When does mutation occur?" this study examined the time of appearance, dominance, and completeness of in vivo Gag mutations in primary HIV-1 subtype C infection.

methodsA primary HIV-1C infection cohort comprised of 8 acutely and 34 recently infected subjects were followed frequently up to 500 days post-seroconversion (p/s). Gag mutations were analyzed by employing single-genome amplification and direct sequencing. Gag mutations were determined in relation to the estimated time of seroconversion. Time of appearance, dominance, and completeness was compared for different types of in vivo Gag mutations.

resultsReverse mutations to the wild type appeared at a median (IQR) of 62 (44;139) days p/s, while escape mutations from the wild type appeared at 234 (169;326) days p/s (p<0.001). Within the subset of mutations that became dominant, reverse and escape mutations appeared at 54 (30;78) days p/s and 104 (47;198) days p/s, respectively (p<0.001). Among the mutations that reached completeness, reverse and escape mutations appeared at 54 (30;78) days p/s and 90 (44;196) days p/s, respectively (p=0.006). Time of dominance for reverse mutations to and escape mutations from the wild type was 58 (44;105) days p/s and 219 (90;326) days p/s, respectively (p<0.001). Time of completeness for reverse and escape mutations was 152 (100;176) days p/s and 243 (101;370) days p/s, respectively (p=0.001). Fitting a Cox proportional hazards model with frailties confirmed a significantly earlier time of appearance (hazard ratio (HR): 2.6; 95% CI: 2.3-3.0), dominance (4.8 (3.4-6.8)), and completeness (3.6 (2.3-5.5)) of reverse mutations to the wild type Gag than escape mutations from the wild type. Some complex mutational pathways in Gag included sequential series of reversions and escapes.

conclusionsThe study identified the timing of different types of in vivo Gag mutations in primary HIV-1 subtype C infection in relation to the estimated time of seroconversion. Overall, the in vivo reverse mutations to the wild type occurred significantly earlier than escape mutations from the wild type. This shorter time to incidence of reverse mutations remained in the subsets of in vivo Gag mutations that reached dominance or completeness.

Indexed as

HIV SeropositivityMutationAcute DiseaseAdultCohort StudiesFemalegag Gene Products, Human Immunodeficiency VirusGenome, ViralHIV-1HIV InfectionsHumansMaleMiddle AgedSequence Analysis, DNATime Factorsgag Gene Products, Human Immunodeficiency Virus

Identifiers

PMID19890401
PMCPMC2768328
OpenAlexW2065581751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.